# A Mass Balance and Pharmacokinetics Study of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment With Poziotinib

> **NCT03804515** · PHASE1 · TERMINATED · sponsor: **Spectrum Pharmaceuticals, Inc** · enrollment: 2 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** 14C-labeled poziotinib

## Key facts

- **NCT ID:** NCT03804515
- **Lead sponsor:** Spectrum Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-06-25
- **Primary completion:** 2020-02-20
- **Final completion:** 2020-06-17
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** COVID
- **Last updated:** 2021-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03804515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03804515, "A Mass Balance and Pharmacokinetics Study of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment With Poziotinib". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03804515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*